$41.56▴ 1.22%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-222.16MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
-97.8%year over year
Weak
Revenue is contracting year over year.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Celldex Therapeutics, Inc. is pre-profit. It is still burning cash while pre-profit. Revenue is contracting year over year.
Key numbers
Valuation
EPS (TTM)$-4.27
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin-32753.6%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$866000.00
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.